Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bella Nguyen

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
BMC Research Notes|December 7, 2018
Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptorsJonathan Chee, Mark W Watson, Abha Chopra, et al.
European Journal of Clinical Nutrition|March 20, 2019
Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of lifeEmily Jeffery, Y C Gary Lee, Robert U Newton, et al.
Pigment Cell & Melanoma Research|October 7, 2019
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanomaRobert Mason, Helen C Dearden, Bella Nguyen, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
BMC Research Notes|December 7, 2018
Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptorsJonathan Chee, Mark W Watson, Abha Chopra, et al.
European Journal of Clinical Nutrition|March 20, 2019
Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of lifeEmily Jeffery, Y C Gary Lee, Robert U Newton, et al.
Pigment Cell & Melanoma Research|October 7, 2019
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanomaRobert Mason, Helen C Dearden, Bella Nguyen, et al.
Pageof 2